Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 2/20 | 0.42 |
| ▸ | APP | P05067 | 4/20 | 0.37 |
| ▸ | SYK | P43405 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL823714 | 0.87 | MAPT (0.40) | APPNPC1ALDH1A1MAPK1RAB9A | |
| SCHEMBL4513221 | 0.86 | RXFP1 (0.43) | NPC1ALDH1A1MAPK1RAB9ANOS1 | |
| SCHEMBL4122428 | 0.85 | MPO (0.39) | NPC1ALDH1A1MAPK1RAB9ANOS1 | |
| SCHEMBL4533861 | 0.85 | PIK3CG (0.43) | NPC1ALDH1A1MAPK1RAB9ADHFR | |
| SCHEMBL4529751 | 0.85 | MAP4K4 (0.44) | NPC1ALDH1A1MAPK1RAB9ADHFR | |
| SCHEMBL4525197 | 0.84 | ALDH1A1 (0.52) | NPC1ALDH1A1MAPK1RAB9ADHFR | |
| SCHEMBL4534215 | 0.84 | ALDH1A1 (0.47) | NPC1ALDH1A1RAB9ANOS1PARP1 | |
| SCHEMBL4526926 | 0.83 | ALDH1A1 (0.43) | NPC1ALDH1A1MAPK1RAB9ADHFR | |
| SCHEMBL4558379 | 0.82 | MAPT (0.42) | APPNPC1ALDH1A1MAPK1RAB9A | |
| SCHEMBL4536355 | 0.81 | TLR8 (0.40) | NPC1ALDH1A1MAPK1RAB9AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232278-B2 | Pyrido(3,2-D)pyrimidines and pharmaceutical compositions useful for treating hepatitis C | GILEAD SCIENCES, INC. (US) | 2012-07-31 | — | — | US | claimed |
| US-20090131414-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C | GILEAD SCIENCES, INC. (US) | 2009-05-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131414-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C | DPYD, TYMP, PNPO | ADK 447/4885APP 4145/4885SYK 3550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.